Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
Withdrawal of the COX-2 inhibitor in Australia following two deaths from liver injury is likely to impact the outcome of FDA’s review.
Withdrawal of the COX-2 inhibitor in Australia following two deaths from liver injury is likely to impact the outcome of FDA’s review.